COVID-19 at the Lille University Hospital between March 30, 2020, and April 8, 2020, in convalescent patients with COVID-19 (n= 6 from the 12 patients in the ICU) sampled after ICU discharge (mean±SD, 21±7 days) and in control healthy donors (n= 8). Compared with healthy donor plasma, plasma from patients with COVID-19 significantly decreased HPMVEC viability, with plasma from patients in the ICU inducing the greatest cytotoxicity (Figure [A]). It is interesting that HPMVEC viability was partially restored to control when plasma from convalescent patients after ICU discharge was tested and compared with plasma of the same patients at the time of ICU admission. Moreover, markers of organ dysfunction were correlated with plasma-induced cytotoxicity (Figure [B]).